Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Professional articles are available in English. Patient articles are available in English, Russian, Spanish, and Polish.

Peptide Therapy in Rheumatic Care

Potential, evidence, and individual decisions

Peptides deserve a thoughtful place in rheumatic care. I support their potential and appropriate use in selected patients. This series explores what individual peptides may offer, the evidence behind them, and the reasons a treatment may or may not suit a particular person.

In this series, I discuss selected peptides that may be helpful for patients with rheumatic diseases. This is not a complete list of potentially useful peptides. I will expand the series over time with additional peptides and articles.

Articles in this series

Peptide Therapy and Rheumatic Conditions: What Might It Help?

A favorable, individualized approach to peptide therapies—and the different problems they may address.

Read article →

What Can We Learn from Peptide Research Around the World?

How to recognize useful evidence, understand uncertainty, and keep regulatory status in perspective.

Read article →

BPC-157: Why Tissue-Repair Research Has Attracted Clinical Interest

The rationale, early human signals, and personal questions behind a widely discussed investigational peptide.

Read article →

General education. A physician with knowledge of rheumatic disease and peptide pharmacology should assess potential benefit and risk individually. The exact peptide, dose, route, personal indications, and contraindications require an individual clinical discussion. Do not change prescribed treatment without your treating clinician.

This is Olga Goodman, MD’s personal educational publication, independent of her clinical practice. It is not a clinic portal and is not linked to clinic accounts or insurance billing.

Copying or republication requires attribution to Olga Goodman, MD and a link to the original article on dr.rheumaview.com. Original article

Share by email

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: Clinical evidencePeptidesTreatment decisions